CymaBay Therapeutics Inc. (NASDAQ: CBAY) is 37.32% higher on its value in year-to-date trading and has touched a low of $1.81 and a high of $11.22 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CBAY stock was last observed hovering at around $8.76 in the last trading session, with the day’s loss setting it -0.15% off its average median price target of $15.00 for the next 12 months. It is also 54.68% off the consensus price target high of $19.00 offered by 11 analysts, but current levels are -7.62% lower than the price target low of $8.00 for the same period.
Currently trading at $8.61, the stock is -14.29% and -9.50% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.57 million and changing -1.71% at the moment leaves the stock 40.28% off its SMA200. CBAY registered 310.00% gain for a year compared to 6-month gain of 156.25%. The firm has a 200-day simple moving average (SMA200) of -$9.32.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
The stock witnessed a -17.45% loss in the last 1 month and extending the period to 3 months gives it a 5.13%, and is -10.31% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.37% over the week and 5.38% over the month.
Distance from 52-week low is 375.69% and -23.26% from its 52-week high.
CymaBay Therapeutics Inc. (CBAY) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for CymaBay Therapeutics Inc. (CBAY) is a “Buy”. 11 analysts offering their recommendations for the stock have an average rating of 1.50, where 0 rate it as a Hold and 0 think it is a “Overweight”. 11 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
CymaBay Therapeutics Inc. is expected to release its quarterly report on 08/10/2023.The EPS is expected to grow by 4.70% this year.
CymaBay Therapeutics Inc. (CBAY) Top Institutional Holders
The shares outstanding are 97.97M, and float is at 80.74M with Short Float at 13.71%.
CymaBay Therapeutics Inc. (CBAY) Insider Activity
A total of 6 insider transactions have happened at CymaBay Therapeutics Inc. (CBAY) in the last six months, with sales accounting for 3 and purchases happening 3 times. The most recent transaction is an insider sale by McWherter Charles,the company’sPresident of R&D. SEC filings show that McWherter Charles sold 21,749 shares of the company’s common stock on May 18 at a price of $9.08 per share for a total of $0.2 million. Following the sale, the insider now owns 15000.0 shares.
CymaBay Therapeutics Inc. disclosed in a document filed with the SEC on May 15 that Quinlan Paul T (General Counsel) sold a total of 5,000 shares of the company’s common stock. The trade occurred on May 15 and was made at $10.37 per share for $51831.0. Following the transaction, the insider now directly holds 0.0 shares of the CBAY stock.
Still, SEC filings show that on Apr 17, KIM DENNIS D (Chief Medical Officer) disposed off 112,219 shares at an average price of $9.54 for $1.07 million. The insider now directly holds 20,000 shares of CymaBay Therapeutics Inc. (CBAY).
CymaBay Therapeutics Inc. (CBAY): Who are the competitors?
The company’s main competitors (and peers) include Bristol-Myers Squibb Company (BMY) that is trading -12.68% down over the past 12 months and Pfizer Inc. (PFE) that is -24.45% lower over the same period. Xencor Inc. (XNCR) is 21.95% up on the 1-year trading charts.